Kyushu University Academic Staff Educational and Research Activities Database
Researcher information (To researchers) Need Help? How to update
ICHIRO IEIRI Last modified date:2022.05.25

Professor / Clinical Pharmaceutics
Kyushu University Hospital

Undergraduate School
医療系統合教育 漢方医薬学
Other Organization
Administration Post
Dean of the School of Pharmaceutical Sciences
Dean of the Graduate School of Pharmaceutical Sciences
Dean of the Faculty of Pharmaceutical Sciences

E-Mail *Since the e-mail address is not displayed in Internet Explorer, please use another web browser:Google Chrome, safari.
 Reseacher Profiling Tool Kyushu University Pure
Introduction of the Hospital Pharmacy, Kyushu University .
Introduction of Clinical Pharmacy Education Center .
Introduction of Department of Clinical Pharmacokinetics. .
Academic Degree
Pharmaceutical Sciences
Country of degree conferring institution (Overseas)
Field of Specialization
Clinical Pharmacokinetics, Pharmacogenomics/Pharmacogenetics, Clinical Pharmacy
ORCID(Open Researcher and Contributor ID)
Total Priod of education and research career in the foreign country
Outline Activities
As the director of pharmacy, I contribute managements of pharmacy and hospital.
I have some classes to students in the faculties of medicine, dental and pharmacy about clinical pharmacology, appropriate drug use etc.
My main research theme is describing large inter-invidiual differences in the pharmacodynamics and pharmacokinetics of clinically useful drugs from the standing points of genetic polymorphisms and gene expression mechanisms.
Another major issue is an application of pharmacometircs to individualized drug therapy.
Other activities include the Councils of some scientific societies and the Editors of some international and domestic journals
My social activities include the director of softball team in a junior school.
Research Interests
  • Development of a new concept if Therapeutic Drug Monitoring from miRNA monitoring in blood.
    keyword : miRNA monitoring, TDM, new concept
  • Contribution of organ- and tissue-specific miRNAs in body fluids on pharmacokinetic and pharmacodynamic changes of clinically useful drugs at metabolic syndromes
    keyword : organ- & tissue-specific miRNA, metabolic syndrome, PK/PD change, lquidbiopsy
  • Expression mechanisms of drug transporters in lifestyle diseases by epitranscriptome
    keyword : エピトランスクリプトーム解析、生活習慣病、トランスポーター、発現変動機構
  • Epigenetic gene expression and pharmcokinetics
    keyword : methylation, histone modification, miRNA, phar,acokinetics, inter-individual avriability
  • Application of metabolome analysis to pharmacoenomic research area.
    keyword : pharmacogenomics, biomarkers, metabolome analyais
  • Meta analysis combined with pharmacometrics
    keyword : Population pk/pd - meta analysis
  • Ethnic differency of pharmacokinetics in Asis
    keyword : Asia, Pharmacokinetics, ethnicity
  • Pharmacodynamic analysis by pharmacometrics using in-hospital medication information
    keyword : Population pk/pd analysis
  • Plasma miRNA concentration as a biomarker for drug transporters
    keyword : Transporter
  • Transporter in vivo functions
    keyword : Transporter
  • Establishment of analytical methofs for drugs in human materials
    keyword : drugs, analytical methods, establishment
  • Useful biomarkers for appropriate drug use.
    keyword : appropriate drug use, biomarkers
  • Microdosing clinical study
    keyword : Microdosingね clinical study
  • Role of miRNAs for expression of pharmacokinetic/pharmacodynamic genes.
    keyword : miRNA, PK/PD, gene expression
  • Epigenetic mechanisms for expression of pharmacokinetic/pharmacodynamic genes.
    keyword : methylation, imprinting, histone, CYP3A4
  • Epigenetic mechanisms for expression of pharmacokinetic/pharmacodynamic genes.
    keyword : methylation, imprinting, histone
  • Population pharmacokinetics
    keyword : population pharmacokinetic pharmacodynamic analysis
  • Investigation for Pharmacogenetics/pharmacogenomics (PGx)
    keyword : Pharmacogenetics、pharmacogenomics
Current and Past Project
  • Applcation of microdosing tests for drug developemental ascenes based on PK/PD/PGx theories.
  • Developement of programs for growing leaders of clinical pharmacists.
  • To accelerate (or developmental support) seeds from individual reseachers in Kyushu University to appropriate clinical situations.
  • Applcation of microdosing tests for PK/PD/PGx scenes.
Academic Activities
1. 家入 一郎, Pharmacogenomics of drug transporters: clinical implications, The Royal Society of Chemistry, RSC Drug Discovery Series No.55, 2016.05.
1. Hirota T, Tanaka T, Takesue H, Ieiri I., Epigenetic regulation of drug transporter expression in human tissues., Expert Opin Drug Metab Toxicol., 13(1):19-30., 2017.01.
2. 家入 一郎, Drug-drug interactions that interfere with statin metabolism., Expert Opin Drug Metab Toxicol., 2015.11.
3. 家入 一郎, Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions., Pharmacogenomics, 2014.01.
4. 家入 一郎, Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs, Drug Metab Pharmacokinet, 2013.01.
5. ICHIRO IEIRI, Y. Akamine, Psychotropic drug-drug interactions involving P-glycoprotein., CNS Drugs, 2012.11.
6. Ichiro Ieiri, Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2)., Drug Metab Pharmacokinet. 2012;27(1):85-105, 2012.03.
7. Ieiri I, Higuchi S, Sugiyama Y, Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs., Expert Opin Drug Metab Toxicol., 5(7):703-29. , 2009.06.
1. Zhang M, Tajima S, Shigematsu T, Noguchi H, Kaku K, Tsuchimoto A, Okabe Y, Egashira N, Ieiri I., Development and Validation of A Liquid Chromatography-Tandem Mass Spectrometry Method to Simultaneously Measure Tacrolimus and Everolimus Concentrations in Kidney Allograft Biopsies After Kidney Transplantation. , Br J Clin Pharmacol., 44, 2, 275-281, 2022.04.
2. Zhang M, Tajima S, Suetsugu K, Hirota T, Tsuchiya Y, Yamauchi T, Yoshimoto G, Miyamoto T, Egashira N, Akashi K, Ieiri I.urata Y, Muraki S, Hirota T, Araki H, Ieiri I., Development and Validation of an LC-MS/MS Method to Quantify Gilteritinib and Its Clinical Application in Patients with FLT3 Mutation-Positive Acute Myelogenous Leukemia., Ther Drug Monit., Feb 9, 2022.02.
3. Kurata Y, Muraki S, Hirota T, Araki H, Ieiri I., Effect of liver cirrhosis on theophylline trough concentrations: A comparative analysis of organ impairment using Child-Pugh and MELD scores., Br J Clin Pharmacol., Mar 36, 2022.03.
4. Yamada T, Soda M, Nishida R, Miyake N, Maeshiro Y, Oida Y, Yamashita Y, Egashira N, Shimono N, Kitaichi K, Ieiri I., Simplified daptomycin dosing regimen for adult patients with methicillin-resistant Staphylococcus aureus infections based on population pharmacokinetic analysis., Drug Metab Pharmacokinet. , Jan 7, 100444, 2022.01.
5. Yamada T, Emoto C, Fukuda T, Motomura Y, Inoue H, Ohga S, Ieiri I., Optimal Teicoplanin Dosing Regimen in Neonates and Children Developed by Leveraging Real-World Clinical Information. , Ther Drug Monit., 44, 3, 404-413, 2022.06.
6. Uchida M, Kawai R, Hisamitsu R, Mai S, Ishida S, Watanabe H, Kawashiri T, Kato K, Hosohata K, Miyamoto T, Egashira N, Nakamura T, Akashi K, Ieiri I., Evaluation of Medication Instruction Sheets for Patients Undergoing R-CHOP Therapy in Non-Hodgkin's Lymphoma., In Vivo., 36, 3, 1461-1467, 2022.05.
7. Uchida M, Murata S, Morikawa H, Yonemitsu H, Ishida S, Suetsugu K, Tsuji T, Watanabe H, Kawashiri T, Kato K, Hosohata K, Miyamoto T, Egashira N, Nakamura T, Akashi K, Ieiri I., Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy., Anticancer Res., 42, 4, 2053-2060, 2022.04.
8. Shigematsu T, Tajima S, Fu R, Zhang M, Itoyama Y, Tsuchimoto A, Egashira N, Ieiri I., The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats. , Life Sci., 288, 120150, 2022.01.
9. Takechi T, Hirota T, Fujii K, Nakahara T, Sakai T, Maeda N, Furue M, Ieiri I., Effect of Genetic Polymorphisms of Human SLC22A3 in the 5'-flanking Region on OCT3 Expression and Sebum Levels in Human Skin. , J Dermatol Sci., 101, 1, 4-13, 2021.01.
10. Belabbas T, Yamada T, Tsuchiya Y, Suetsugu K, Egashira N, Ieiri I., Development and Full Validation of a Bioanalytical Method for Quantifying Letermovir in Human Plasma Using Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry., Chem Pharm Bull (Tokyo)., 69, 7, 646-651, 2021.07.
11. Suetsugu K, Muraki S, Fukumoto J, Matsukane R, Mori Y, Hirota T, Miyamoto T, Egashira N, Akashi K, Ieiri I., Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study. , Drugs R D., 21, 4, 419-429, 2021.12.
12. Kurata Y, Muraki S, Hirota T, Araki H, Ieiri I., Reduced theophylline clearance due to hepatic congestion secondary to right heart failure - A population pharmacokinetic study. , Drug Metab Pharmacokinet. , Dec14, 100403, 2021.12.
13. Matsukane R, Watanabe H, Hata K, Suetsugu K, Tsuji T, Egashira N, Nakanishi Y, Okamoto I, Ieiri I., Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. , Sci Rep., 11, 15057, 2021.07.
14. Araki H, Takenaka T, Takahashi K, Yamashita F, Matsuoka K, Yoshisue K, Ieiri I., A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS-114. , CPT Pharmacometrics Syst Pharmacol., Dec.23, 2021.12.
15. Tateishi H, Miyazu D, Kurinami M, Ieiri I, Hirakawa M, Watanabe H., Hypoglycemia possibly caused by CYP2C9-mediated drug interaction in combination with bucolome: a case report. , J Pharm Health Care Sci., 7, 1, 39, 2021.11.
16. Fu R, Tajima S, Shigematsu T, Zhang M, Tsuchimoto A, Egashira N, Ieiri I, Masuda S., Establishment of an experimental rat model of tacrolimus-induced kidney injury accompanied by interstitial fibrosis , Toxicol Lett., 341, 43-50, 2021.05.
17. Ito S, Hirota T, Yanai M, Muto M, Watanabe E, Taya Y, Ieiri I., Effects of Genetic Polymorphisms of Cathepsin A on Metabolism of Tenofovir Alafenamide. , Genes (Basel)., 12, 12, 2026, 2021.12.
18. Nagata K, Tsuji T, Suetsugu K, Muraoka K, Watanabe H, Kanaya A, Egashira N, Ieiri I., Detection of overdose and underdose prescriptions-An unsupervised machine learning approach., PLoS One., 16, 11, e0260315, 2021.11.
19. Hirota T, Fujita Y, Ieiri I., An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins., Expert Opin Drug Metab Toxicol. , 16, 9, 809-822, 2020.09.
20. Ishida S, Makihara Y, Watanabe H, Nakashima T, Nagata K, Suetsugu K, Tsuji T, Hata K, Ikeda M, Ikebe M, Minami H, Watanabe H, Nakata K, Nakamura M, Egashira N, Ieiri I., Risk Factors for Gemcitabine-Induced Vascular Pain in Patients With Pancreatic Cancer., Ann Pharmacother., 55, 6, 738-744, 2021.06.
21. Tomoki Takechi, Takeshi Hirota, Kazushi Fujii, Takeshi Nakahara, Tatsuya Sakai, Natsumi Maeda, Masutaka Furue, Ichiro Ieiri , Effect of Genetic Polymorphisms of Human SLC22A3 in the 5'-flanking Region on OCT3 Expression and Sebum Levels in Human Skin , J Dermatol Sci., 101, 1, 4-13, 2021.01.
22. Hata K, Suetsugu K, Egashira N, Makihara Y, Itoh S, Yoshizumi T, Tanaka M, Kohjima M, Watanabe H, Masuda S, Ieiri I., Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma, Cancer Chemother Pharmacol., 86, 6, 803-813, 2020.12.
23. Tajiri A, Hirota T, Kawano S, Yonamine A, Ieiri I., Regulation of Organic Anion Transporting Polypeptide 2B1 Expression by MicroRNA in the Human Liver , Mol Pharm., 17, 8, 2821-2830, 2020.08.
24. Kurata Y, Muraki S, Kashihara Y, Hirota T, Araki H, Ieiri I., Differences in Theophylline Clearance Between Patients With Chronic Hepatitis and Those With Liver Cirrhosis , Ther Drug Monit. , 42, 6, 829-834, 2020.12.
25. Lee N, Maeda K, Fukizawa S, Ieiri I, Tomaru A, Akao H, Takeda K, Iwadare M, Niwa O, Masauji T, Yamane N, Kajinami K, Kusuhara H, Sugiyama Y., Microdosing Clinical Study to Clarify Pharmacokinetic and Pharmacogenetic Characteristics of Atorvastatin in Japanese Hypercholesterolemic Patients, Drug Metab Pharmacokinet., 34, 6, 387-395, 2019.12.
26. Miyake T, Mizuno T, Takehara I, Mochizuki T, Kimura M, Matsuki S, Irie S, Watanabe N, Kato Y, Ieiri I, Maeda K, Ando O, Kusuhara H., Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters , Drug Metab Dispos., 47, 11, 1270-1280, 2019.11.
27. Higuchi K, Yamashita D, Kashihara Y, Kakara M, Hirota T, Hirakawa M, Ieiri I., Population Pharmacokinetic Analysis of Phenytoin After Intravenous Administration of Fosphenytoin in Adult and Elderly Epileptic Patients , Ther Drug Monit. , 41, 5, 674-680, 2019.10.
28. Mori D, Kashihara Y, Yoshikado T, Kimura M, Hirota T, Matsuki S, Maeda K, Irie S, Ieiri I, Sugiyama Y, Kusuhara H., Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers., Drug Metab Pharmacokinet. 2019 Feb;34(1):78-86. , 34, 1, 78-86, 2019.02.
29. Inoue H, Tamaki Y, Kashihara Y, Muraki S, Kakara M, Hirota T, Ieiri I., Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis., Br J Clin Pharmacol. , 85, 2, 393-402, 2019.06.
30. Kashihara Y, Terao Y, Yoda K, Hirota T, Kubota T, Kimura M, Matsuki S, Hirakawa M, Irie S, Ieiri I., Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation., Eur J Clin Pharmacol., 75, 3, 351-361, 2019.03, パーキンソン病の患者の多くは便秘を併発することから、治療薬として酸化マグネシウム(MgO)が処方され、治療ガイドラインにおいても第一選択薬とされている。一方、多くの患者は治療にl-dopa/carbidopa(LDCD)を服用している。我々は、MgOがLDの分解を促進し、LDの血中濃度を低下させること、その背景には、MgOがCDを直接分解し、その2次的作用としてLDの分解を促進することをin vitro実験、動物実験、健常成人を対象とした臨床試験により明らかにした。これらの相互作用の臨床的意義をModel-based Meta-analysisの手法を用い検討した結果、LDの効果の減弱の原因になることが示唆された。治療ガイドラインの見直しの必要性が示唆された。.
31. Tamaki Y, Maema K, Kakara M, Fukae M, Kinoshita R, Kashihara Y, Muraki S, Hirota T, Ieiri I., Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models., Drug Metab Pharmacokinet. , 33, 6, 264-269, 2018.12.
32. Fujita S, Hirota T, Sakiyama R, Baba M, Ieiri I., Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy., J Neurochem. , 148, 3, 373-385, 2019.02.
33. Takesue H, Hirota T, Tachimura M, Tokashiki A, Ieiri I., Nucleosome Positioning and Gene Regulation of the SGLT2 Gene in the Renal Proximal Tubular Epithelial Cells., Mol Pharmacol., 94, 3, 953-962, 2018.09.
34. Hirota T, Muraki S, Ieiri I., Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer., Clin Pharmacokinet. , 58, 4, 403-420, 2019.05.
35. Takechi T, Kumokawa T, Kato R, Higuchi T, Kaneko T, Ieiri I., Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma., J Clin Pharmacol., 58, 10, 1361-1370, 2018.10.
36. Takechi T, Hirota T, Sakai T, Maeda N, Kobayashi D, Ieiri I., Interindividual Differences in the Expression of ATP-Binding Cassette and Solute Carrier Family Transporters in Human Skin: DNA Methylation Regulates Transcriptional Activity of the Human ABCC3 Gene., Drug Metab Dispos., 46, 5, 628-635, 2018.05.
37. Eguchi R, Onozuka D, Ikeda K, Kuroda K, Ieiri I, Hagihara A., Psychological assessment of acute schizophrenia patients who experienced seclusion either alone or in combination with restraint., Int J Psychiatry Med., 53, 3, 171-188, 2018.05.
38. Tanaka T, Hirota T, Ieiri I., Relationship between DNA Methylation in the 5' CpG Island of the SLC47A1 (Multidrug and Toxin Extrusion Protein MATE1) Gene and Interindividual Variability in MATE1 Expression in the Human Liver., Mol Pharmacol. , 93, 1, 1-7, 2018.01.
39. Muraki S, Moriki K, Shigematsu S, Fukae M, Kakara M, Yamashita D, Hirota T, Takane H, Shimada M, Hirakawa M, Ieiri I., Population Pharmacodynamic Analysis of Uric Acid-Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals., J Clin Pharmacol., 10.1002/jcph.1023. , 2017.10.
40. Miyake T, Mizuno T, Mochizuki T, Kimura M, Matsuki S, Irie S, Ieiri I, Maeda K, Kusuhara H., Involvement of Organic Cation Transporters in the Kinetics of Trimethylamine N-oxide., Pharm Sci., 10.1016/j.xphs.2017.04.067. , 106, 9, 2542-2550, 2017.09.
41. Kashihara Y, Ieiri I, Yoshikado T, Maeda K, Fukae M, Kimura M, Hirota T, Matsuki S, Irie S, Izumi N, Kusuhara H, Sugiyama Y., Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP., Pharm Sci., 10.1016/j.xphs.2017.03.010. , 106, 9, 2688-2694, 2017.09.
42. Hovelson DH, Xue Z, Zawistowski M, Ehm MG, Harris EC, Stocker SL, Gross AS, Jang IJ, Ieiri I, Lee JE, Cardon LR, Chissoe SL, Abecasis G, Nelson MR., Characterization of ADME gene variation in 21 populations by exome sequencing., Pharmacogenet Genomics., 10.1097/FPC.0000000000000260., 27, 3, 89-100, 2017.05.
43. 家入 一郎, Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer., Cancer Chemother Pharmacol. , 78, 5, 1013-1023, 2016.11.
44. 家入 一郎, Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines., Sci Rep. , 6, 32299, 2016.08, A variant in the breast cancer resistance protein (BCRP) gene, 421C> A is a useful biomarker for describing large inter-individual differences in the pharmacokinetics of sulfasalazine (SASP), a BCRP substrate. However, large intra-genotypic variability still exists in spite of the incorporation of this variant into the pharmacokinetics of SASP. Since miR-328 negatively regulates BCRP expression in human tissues, we hypothesized that exosomal miR-328 in plasma, which leaks from the intestines, is a possible biomarker for estimating BCRP activity in the human intestines. We established an immunoprecipitation-based quantitative method for circulating intestine-derived miR-328 in plasma using an anti-glycoprotein A33 antibody. A clinical study was conducted with an open-label, non-randomized, and single-arm design involving 33 healthy participants. Intestine-derived exosomal miR-328 levels positively correlated (P < 0.05) with SASP AUC0-48, suggesting that subjects with high miR-328 levels have low intestinal BCRP activity, resulting in the high AUC of SASP. Circulating intestine-derived exosomal miR-328 in plasma has potential as a possible biomarker for estimating BCRP function in the human intestines..
45. 家入 一郎, Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene., Br J Clin Pharmacol., 80, 5, 1236-1237, 2015.11.
46. 家入 一郎, Neonatal Dubin-Johnson syndrome: novel compound heterozygous mutation in the ABCC2 gene., Pediatr Int., 56, 5, e62-e64, 2014.10.
47. 家入 一郎, Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers., J Clin Pharm Ther. , 40, 1, 98-103, 2014.09.
48. 家入 一郎, Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment., Pharmacogenet Genomics, 2014.07.
49. 家入 一郎, Identification and functional characterization of novel nonsynonymous variants in the human multidrug and toxin extrusion 2-k., Drug Metab Dispos, 42, 9, 1432-1437, 2014.09.
50. 家入 一郎, Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers., Eur J Clin Pharmacol, 70, 9, 1087-1095, 2014.09.
51. 家入 一郎, Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records., Br J Clin Pharmacol, 2014.04.
52. 家入 一郎, Influences of artificial heart-lung machine operation on the binding sites of albumin: possibility of an effective administration plan., Int J Artif Organs, 37, 2, 99-108, 2014.02.
53. 家入 一郎, Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis., J Clin Pharmacol, 54, 8, 937-948, 2014.08.
54. 家入 一郎, Mechanism of the 24-hour rhythm of tumor necrosis factor-alpha formed by onset of rheumatoid arthritis., Chronobiol Int., 31, 4, 564-571, 2014.05.
55. 家入 一郎, Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions., Pharmacogenomics., 14, 4, 1745-1764, 2013.11.
56. 家入 一郎, Association between DNA methylation in the miR-328 5'-flanking region and inter-individual differences in miR-328 and BCRP expression in human placenta., PLoS One. , 21, 8, e72906, 2013.08.
57. 家入 一郎, MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells., BMC Cancer, 13, 1, 369, 2013.08.
58. 家入 一郎, MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells., BMC Cancer, 13, 1, 369, 2013.08.
59. 家入 一郎, Direct and rapid genotyping of SLCO1B1 388A>G and 521T>C in human blood specimens using the SmartAmp-2 method., AAPS J, 15, 2, 618-622, 2013.03.
60. 家入 一郎, Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs., J Clin Pharmacol, 53, 6, 654-661, 2013.06.
61. 家入 一郎, Role of Methotrexate Polyglutamation and Reduced Folate Carrier 1 (RFC1) Gene Polymorphisms in Clinical Assessment Indexes., Drug Metab Pharmacokinet, 28, 5, 442-445, 2013.10.
62. ICHIRO IEIRI, M. Fukaw, K. Maeda, Y. Suguyama, Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing., Int J Clin Pharmacol Ther., 10.5414/CP201763., 50, 10, 689-700, 2012.10.
63. ICHIRO IEIRI, K. Sonoki, M. Iwase, S. Ohdo, Telmisartan and N-acetylcysteine suppress group V secretory phospholipase A2 expression in TNFα-stimulated human endothelial cells and reduce associated atherogenicity., J Cardiovasc Pharmacol., 10.1097/FJC.0b013e3182646ccc., 60, 4, 367-374, 2012.10.
64. ICHIRO IEIRI, S. Endo, A. Fukuhori, S. Tokuhiro, Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure., J Hum Genet., 10.1038/jhg.2012.63. , 57, 8, 531-544, 2012.08.
65. ICHIRO IEIRI, H. Jeon, IJ. Jang, KS. Lin, Apple juice greatly reduces systemic exposure to atenolol., Br J Clin Pharmacol. , 10.1111/j.1365-2125.2012.04324.x., 75, 1, 172-179, 2013.01.
66. ICHIRO IEIRI, K.Kato, H.Kusuhara, Y. Sugiyama, Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals., Pharmacogenet Genomics., 10.1097/FPC.0b013e3283517012., 22, 5, 344-354, 2012.05.
67. ICHIRO IEIRI, Y. Date, Y. Nishibatake, Takeshi Hirota, Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues., Lung Cancer, 10.1016/j.lungcan.2011.12.018. , 166, 6, 1793-1803, 2012.07.
68. Kusuhara H, Furuie H, Inano A, Sunagawa A, Yamada S, Wu C, Fukizawa S, Morimoto N, Ieiri I, Morishita M, Sumita K, Mayahara H, Fujita T, Maeda K, Sugiyama Y., Pharmacokinetic interaction study of sulfasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP., Br J Pharmacol., 10.1111/j.1476-5381.2012.01887.x., 2012.02.
69. Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, Ieiri I, Siemers ER., Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease., Clin Neuropharmacol., 35, 1, 25-9, 2012.02.
70. Egashira K, Sasaki H, Higuchi S, Ieiri I., Food-drug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats., Drug Metab Pharmacokinet., 27, 2, 242-7, 2012.04.
71. Ieiri I, Nishimura C, Maeda K, Sasaki T, Kimura M, Chiyoda T, Hirota T, Irie S, Shimizu H, Noguchi T, Yoshida K, Sugiyama Y., Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose., Pharmacogenet Genomics. , 2011 Aug;21(8):495-505, 2011.08.
72. Ieiri I, Doi Y, Maeda K, Sasaki T, Kimura M, Hirota T, Chiyoda T, Miyagawa M, Irie S, Iwasaki K, Sugiyama Y., Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose., J Clin Pharmacol., in press, 2011.05.
73. Saito J, Hirota T, Kikunaga N, Otsubo K, Ieiri I., Interindividual differences in placental expression of the SLC22A2 (OCT2) gene: Relationship to epigenetic variations in the 5'-upstream regulatory region., J Pharm Sci. , 2011 Sep;100(9):3875-83., 2011.09.
74. Sasaki T, Hirota T, Ryokai Y, Kobayashi D, Kimura M, Irie S, Higuchi S, Ieiri I., Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function., Drug Metab Pharmacokinet., in press, 2011.04.
75. Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, Horii T, Otsubo K, Ieiri I., Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients., Antimicrob Agents Chemother. , 2011 May;55(5):1867-73., 2011.05.
76. Ide T, Sasaki T, Maeda K, Higuchi S, Sugiyama Y, Ieiri I., Quantitative Population Pharmacokinetic Analysis of Pravastatin Using an Enterohepatic Circulation Model Combined With Pharmacogenomic Information on SLCO1B1 and ABCC2 Polymorphisms., J Clin Pharmacol. , 49(11):1309-17

, 2009.11.
77. Sasaki T, Tabuchi H, Higuchi S, Ieiri I., Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting., Pharmacogenomics. , 10(8):1257-66, 2009.08.
78. Ieiri I, Higuchi S, Sugiyama Y., Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs., Expert Opin Drug Metab Toxicol. , 5(7):703-29, 2009.05.
79. Kodama A, To H, Kinoshita T, Ieiri I, Higuchi S., Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice., J Pharm Pharmacol. , 61(5):615-21, 2009.05.
80. Sugahara H, Maebara C, Ohtani H, Handa M, Ando K, Mine K, Kubo C, Ieiri I, Sawada Y. , Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease., Eur J Clin Pharmacol., 65(7):699-704. , 2009.06.
81. Takane H, Kawamoto K, Sasaki T, Moriki K, Moriki K, Kitano H, Higuchi S, Otsubo K, Ieiri I., Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy., Cancer Chemother Pharmacol., 63(6):1165-9., 2009.05.
82. Suwannakul S, Ieiri I, Kimura M, Kawabata K, Kusuhara H, Hirota T, Irie S, Sugiyama Y, Higuchi S., Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism., J Hum Genet., 53(10):899-904., 2008.06.
83. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, Higuchi S, Sugiyama Y., Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans., Clin Pharmacol Ther. , 84(1):95-103., 2008.06.
84. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I., Polymorphism in human organic cation transporters and metformin action., Pharmacogenomics., 9(4):415-22., 2008.04.
85. Hirota T, Takane H, Higuchi S, Ieiri I., Epigenetic regulation of genes encoding drug-metabolizing enzymes and transporters; DNA methylation and other mechanisms., Curr Drug Metab., 9(1):34-8., 2008.01.
86. Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y., SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers., Clin Pharmacol Ther. , in press, 2007.04.
87. Shikata E., Ieiri I., Ishiguro S., Takane H., Ohgi S. and Otsubo K., Multiple gene polymorphisms and warfarin sensitivity., Eur J Clin Pharmacol, 62(10):881-3, 2006.10.
88. Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, Ieiri I., Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin., J Hum Genet. , 52(2):117-22, 2007.02.
89. Takane H., Miyata M., Burioka N., Shigemasa C., Shimizu E., Otsubo K. and Ieiri I., Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy., J Hum Genet, 51; 822-826, 2006.06.
90. Maeda K., Ieiri I., Yasuda K., Fujino A., Fujiwara H., Otsubo K., Hirano M., Watanabe T., Kitamura Y., Kusuhara H. and Sugiyama Y., Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril., Clin Pharmacol Ther, 79; 427-439, 2006.05.
91. Takane H, Nosaka A, Wakushima H, Hosokawa K, Ieiri I., Rifampin reduces the analgesic effect of transdermal fentanyl.
, Ann Pharmacother. , 39: 2139-40, 2005.12.
92. Ieiri I., Kimura M., Irie S., Urae A., Otsubo K. and Ishizaki T., Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status., Pharmacogenetics and Genomics, 15; 851-859, 2005.12.
1. Ichiro Ieiri, Challenges for application of epigenetic concepts to pharmacogenomics in humans, 18th World Comgress of Basic and Clinical Pharmacology, 2018.06.
2. 家入 一郎, Value and limitations of cutting-edge science (e.g., gene therapy and pharmacogenomics ) to patient care here and now
, FIP's World Congress of Pharmacy and Pharmaceutical Sciences, 2015.09.
3. I will present candidate multiple gene analysis for prediction of individual warfarin response..
Educational Activities
My education activities include "Clinical Pharmacokinetics, Clinical Pharmacology and Clinical Pharmacy Practices" for some degree students in the Faculties of Medicine, Dental, and Pharmacy.
Professional and Outreach Activities
Coach for base ball team in a area of junior shcool..